<DOC>
	<DOCNO>NCT00954876</DOCNO>
	<brief_summary>The combination capecitabine cetuximab first-line therapy result improve progression free survival compare single agent capecitabine patient KRAS wild type colorectal cancer . Patients able willing take Oxaliplatin/Irinotecan combination therapy eligible study .</brief_summary>
	<brief_title>Study Capecitabine Cetuximab First-Line Therapy Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria Metastatic colorectal cancer Tumor classify WT KRAS At least 18 yrs age ECOG PS 0,1 2 Evidence adequate organ function Measurable disease per RECIST criterion Have least two follow criterion : Age &gt; 65 year ECOG PS 1 2 Serum Albumin &lt; equal 3.5g/dL Prior RT abdomen pelvis Stopped firstline combination systemic chemotherapy &lt; 6 week duration Exclusion Criteria Tumors classify KRAS mutation Prior therapy cetuximab , panitumumab agent target EGFR Prior exposure biologic Known sensitivity cetuximab 5FU ( mark intolerance 5FU ) Known DPD deficiency Uncontrolled angina myocardial infarction within previous 12 month Concurrent severe uncontrolled medical illness Known uncontrolled CNS metastasis Bowel disease associate chronic diarrhea Major surgery within 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>